ICH Project The 42nd ICH Informal Meeting (Web-based)

December 01, 2020

The 42nd ICH Informal Meeting was held on the web on December 16, 2020 to share information on the progress of ICH with the general public and companies in charge of drug development and safety assurance.

In previous years, this meeting has been held as an "immediate report" to report on the progress of topics that were intensively discussed face-to-face at the ICH plenary meeting. However, this year, due to the spread of the new coronavirus, two ICH plenary meetings were held virtually, and as a result, intensive face-to-face discussions on the topics could not be held.

The program, timetable, and presentation materials for this meeting are attached below for your direct review.
Unauthorized copying or reproduction of the attached contents is strictly prohibited.

Date, Time, and Location

Date and time Method of the event
Wednesday, December 16, 2020, 13:00-16:40 Online (WebEx)

Information, Program

Information/Program

Presentation Materials

Presentations Speakers

01_ICH Trends (1,430KB)

Egyo Tanabe (Ministry of Health, Labour and Welfare)

02. Trend of ICH - from JPMA's point of view - (2,230KB)

Masashi Yokota (JPMA)

03_S1 (R1): Rodent Carcinogenicity Studies for Human Pharmaceuticals
Carcinogenicity Studies for Pharmaceuticals (Revised) (634KB)

Kumiko OGAWA (NIHS)

04_S12:Biodistribution Studies for Gene Therapy Products
Nonclinical Biodistribution Considerations for Gene Therapy Products (296KB)

Yuto Takishima (NIH)

05_Q3C(R8):Residual Solvent Residual Solvent for Pharmaceuticals
_Q3D(R2):Revision of Guideline for Elemental Impurities in Pharmaceuticals (472KB)

Akihiko Hirose (NIHS)

06_Q9(R1):Quality Risk Management Quality Risk Management (166KB) (in Japanese)

Tomoaki SAKAMOTO (NIHS)

07_Q3E:Guideline for Extractables and Leachables (E&L)
Evaluation and Management of Leachables and Leachables of Pharmaceutical and Biopharmaceutical Products (373KB)

Hiroshi Takeda (Japan Science and Technology Agency)

08_Q5A(R2): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin (575KB)

Yoji SATO (NIHN)

09_Q2(R2)/Q14: Analytical Procedure Development and Revision of Q2(R1)
Validation of Analytical Procedures "Analytical Method Validation Guidelines" (406KB)

Akiko Mase (NIH)

10_Q13: Continuous Manufacturing of Drug Substances and Drug Products
Continuous Manufacturing of Drug Substances and Drug Products (316KB)

Yasuhiro MATSUI (JPMA)

11_M13:Bioequivalence for Immediate-Release Solid Oral Dosage Forms
Bioequivalence Evaluation of Immediate-Release Solid Oral Dosage Forms (209KB)

Ryosuke Kuribayashi (NIH)

12_E8(R1): Revision of General Considerations for Clinical Trials
General Considerations for Clinical Studies (1,013KB)

Hiroshi Sakaguchi (NIH)

13_E11A:Pediatric Extrapolation Extrapolation in Pediatric Drug Development (249KB) (in Japanese)

Shinichi Kijima (NIH)

14_E20: Adaptive Clinical Trials Adaptive Clinical Trials (157KB)

Tomonori Ando (NIMS)

15_M11: CeSHarP (1,153KB)

Ken Sakushima (NIMS)

16_M12: Drug Interaction Studies Drug Interaction Studies (964KB)

Shinhiro Hoshino (NIMS)

 

Share this page

TOP